Research programme: PLR 14 - PLIVA d.d.

Drug Profile

Research programme: PLR 14 - PLIVA d.d.

Alternative Names: PLR 14 research programme - PLIVA d.d.

Latest Information Update: 16 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PLIVA d.d.
  • Class Anti-inflammatories; Antirheumatics; Small molecules
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Crohn's disease; Rheumatoid arthritis

Most Recent Events

  • 15 Jul 2005 This programme is still in active development for Rheumatoid arthritis
  • 15 Apr 2005 No development reported - Preclinical for Crohn's disease in Croatia (PO)
  • 05 Jul 2002 Preclinical trials in Crohn's disease in Croatia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top